Press releases and news
2025
Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Change in number of shares and votes in Camurus
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Exercise in Camurus’ employee stock options program 2022/2026
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2025/2028
Resolutions at the annual general meeting 2025 in Camurus
Camurus to present at Jefferies Global Healthcare Conference
Camurus’ Interim Report January-March 2025
Camurus appoints Anders Vadsholt as Chief Financial Officer
Camurus launches Buvidal® weekly and monthly in Portugal
Camurus Annual Report for 2024
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
Notice of annual general meeting 2025 in Camurus AB (publ)
Camurus’ CEO Fredrik Tiberg receives The Arthur D. Little Nordic Life Science Award
Camurus receives EthiFinance ESG Platinum Medal
Jon Garay Alonso will leave position as Camurus’ CFO
Camurus’ Full Year Report 2024
Camurus’ fourth quarter and full year 2024 earnings above previous estimates
Buvidal® weekly and monthly – now available to patients in Switzerland
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.